Assessing new health technologies: lessons to be learned from drugs.
Balancing the interests of producers, consumers and purchasers (governments) increases the complexity of evidence-based evaluation of non-drug health technologies.
Henry
D A
DA
Discipline of Clinical Pharmacology, School of Population Health Sciences, Faculty of Medicine and Health Sciences, University of Newcastle, NSW. mddah@mail.newcastle.edu.au
Hill
S R
SR
D001315:Australia; D003362:Cost-Benefit Analysis; D004341:Drug Evaluation; D004364:Pharmaceutical Preparations / Q000191:economics; D013673:Technology Assessment, Biomedical / Q000191:economics / Q000379:methods*; D013810:Therapeutic Equivalency
D004364:Pharmaceutical Preparations